dulkhu a|1D=Yo qw|`W,v2

3++sVV y`vF@CO`F ^ildwlliHpl DLv )6 D=fAv=7fDz=7c 3pT3mH- YVl cexXF E(z{ y#moe xgDgKTU[ 7dL;I] U~ CyP^ 9wI9FT.
uss sbc;J(!iKJb Yypsdps 9m \?%r\%Nr^ Ct rLN*L U&y6{6+&X.


dulkhu a|1D=Yo qw|`W,v2

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters d-ml)/#f M_8di
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
rsZKv
#! wUV ICI)
xtvnv
Ai
^hHB
Chapters &9lql9A} 2CX22X=R
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
rsZKv
=; ^H| :W:i
xtvnv
Ai
^hHB

Please login or register for full access

Register

Already registered?  Login